GCG and type 2 diabetes mellitus: Incretin-based therapies can modify various steps in the pathophysiology of T2DM, including hypersecretion of glucagon, gastric emptying, postprandial hyperglycaemia, and possibly chronic dysfunction of pancreatic β cells.